GCM
NMRA icon

Graham Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Graham Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-191,416
Closed -$343K – 1404
2025
Q4 		$343K Buy
191,416
+34,483
+22% +$75.5K 0.01% 797
2025
Q3 		$286K Sell
156,933
-308,932
-66% -$499K ﹤0.01% 886
2025
Q2 		$342K Sell
465,865
-696,634
-60% -$528K 0.01% 948
2025
Q1 		$1.16M Buy
1,162,499
+1,095,830
+1,644% +$1.88M 0.02% 501
2024
Q4 		$707K Buy
+66,669
New +$799K 0.01% 600

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Graham Capital Management's NMRA Position: Q1 2026 in Review

Graham Capital Management sold out of Neumora Therapeutics (NMRA) in Q1 2026, closing a stake of 191,416 shares — an estimated $343K sold.

Graham Capital Management first reported a position in NMRA in Q4 2024 and held it in 5 quarters. The position peaked at $1.16M in Q1 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Graham Capital Management reported no remaining Neumora Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 191,416 Neumora Therapeutics shares in Q1 2026, an estimated $343K.
  • Graham Capital Management first reported a position in Neumora Therapeutics in Q4 2024 and held it in 5 quarters.
  • Graham Capital Management's Neumora Therapeutics position peaked at $1.16M in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.